Reuters logo
2 months ago
BRIEF-Semnur Pharmaceuticals announces successful phase 1/2 trial for its lead product, SP-102
June 26, 2017 / 11:20 AM / 2 months ago

BRIEF-Semnur Pharmaceuticals announces successful phase 1/2 trial for its lead product, SP-102

June 26 (Reuters) - Semnur Pharmaceuticals Inc:

* trial also showed that adverse events were comparable between two treatments

* Semnur pharmaceuticals inc announces successful phase 1 / 2 trial in patients with radicular pain for its lead product, SP-102

* trial was conducted in patients with radicular pain, achieved its primary pharmacokinetic endpoint

* announced successful phase 1 / 2 pharmacokinetic bridging trial of lead product SP-102 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below